:-Welcome to Fresenius Kabi India Pvt Ltd. A 100% subsidiary of Fresenius AG:-

We are dedicated to supporting health care professionals in the best therapy of chronically and critically ill patients by providing pharmaceuticals and medical devices. Our products are vital in the acute, surgical and therapeutic treatment of patients and are used in the hospital and in outpatient care.

Our 30,000 employees worldwide share one passion: "caring for life". It is our commitment to what matters most in health care - improving a patient's quality of life.

CME on Total Cancer Care in the recently concluded Indian Cancer Congress 21st to 24th November 2013 at the Kempinski, Delhi
Fitch confirms Fresenius BB+ rating; outlook positive
U.S. Propofol market share update (17.3.14)
U.S Propofol market share update ( 9.1.2.'13)
Fresenius Kabi invests in new technologies, expands production site in Austria
Fresenius begins trading in OTCQX International Premier in the U.S
All corporate credit ratings for Fresenius SE & Co KGaA confirmed
Fresenius relases films and interactive company history to mark its 100th anniversary
Fresenius annouces decision on biotechnology business
Fresenius Kabi completes acquisition of Fenwal Holdings, Inc
Press release - Fresenius Kabi raises 2012 outlook
Fresenius Kabi acquires Fenwal Holdings, Inc.! For more details click here .........